NCT01731665 Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.
| NCT ID | NCT01731665 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Asan Medical Center |
| Condition | Crohn's Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2012-12 |
| Primary Completion | 2029-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2012-12 with a primary completion date of 2029-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the incidence, prevalence, clinical characteristics and prognosis of Crohn's disease and ulcerative colitis over time in a district of Seoul, Korea.
Eligibility Criteria
Inclusion Criteria: * Definite cases of CD and UC Patients are diagnosed with CD if they meet at least 2 of the following criteria: 1. clinical history of abdominal pain, weight loss, malaise, diarrhea, and/or rectal bleeding 2. endoscopic findings of mucosal cobblestoning, linear ulceration, skip areas, or perianal disease 3. radiologic findings of stricture, fistula, mucosal cobblestoning, or ulceration 4. macroscopic appearance of bowel wall induration, mesenteric lymphadenopathy, and "creeping fat" at laparotomy 5. pathologic findings of transmural inflammation and/or epithelioid granulomas Only patients who meet these criteria for at least 2 months are included. Patients are diagnosed with UC only if all 3 of the following criteria are present 1. a typical history of diarrhea or blood and pus or both in the stool for longer than 4 weeks 2. a typical sigmoidoscopic or colonoscopic picture with diffusely granular, friable, or ulcerated mucosa without rectal sparing or skip lesions or radiological signs of characteristic continuous granular or ulcerated mucosa 3. characteristic histopathological signs of inflammation on biopsy Exclusion Criteria: * IBD unclassified * Ethnic groups other than Korean
Contact & Investigator
Suk-Kyun Yang, M.D.
PRINCIPAL INVESTIGATOR
Asan Medical Center
Frequently Asked Questions
Who can join the NCT01731665 clinical trial?
This trial is open to participants of all sexes, studying Crohn's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01731665 currently recruiting?
Yes, NCT01731665 is actively recruiting participants. Contact the research team at sky@amc.seoul.kr for enrollment information.
Where is the NCT01731665 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT01731665 clinical trial?
NCT01731665 is sponsored by Asan Medical Center. The principal investigator is Suk-Kyun Yang, M.D. at Asan Medical Center. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.